Search Results - Véronique Dièras

Refine Results
  1. 1
    The taxanes: toxicity and quality of life considerations in advanced ovarian cancer

    The taxanes: toxicity and quality of life considerations in advanced ovarian cancer by Jean Paul Guastalla, Véronique Dièras

    Published 2003
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  2. 2
    Expert perspectives on biosimilar monoclonal antibodies in breast cancer

    Expert perspectives on biosimilar monoclonal antibodies in breast cancer by Javier Cortés, Giuseppe Curigliano, Véronique Dièras

    Published 2014
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  3. 3
    The role of tyrosine kinase inhibitors in the treatment of HER2+ metastatic breast cancer

    The role of tyrosine kinase inhibitors in the treatment of HER2+ metastatic breast cancer by Fanny Le Du, Véronique Dièras, Giuseppe Curigliano

    Published 2021
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  4. 4
    First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients

    First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients by D.W. Miles, Véronique Dièras, Javier Cortés, Anja Duenne, Jingbo Yi, Joyce O’Shaughnessy

    Published 2013
    Get full text
    Revisão
    Save to List
    Saved in:
  5. 5
    Meningeal carcinomatosis in patients with breast carcinoma: Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen

    Meningeal carcinomatosis in patients with breast carcinoma: Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen by Karim Fizazi, Bernard Asselain, Anne Vincent‐Salomon, Michel Jouve, Véronique Dièras, Thao Palangié, Philippe Beuzeboc, Thierry Dorval, P Pouillart

    Published 1996
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Cabazitaxel in patients with advanced solid tumours: Results of a Phase I and pharmacokinetic study

    Cabazitaxel in patients with advanced solid tumours: Results of a Phase I and pharmacokinetic study by Véronique Dièras, Alain Lortholary, Valérie Laurence, R. Delva, V. Girre, Alain Livartowski, Sylvie Assadourian, Dorothée Sémiond, Jean‐Yves Pierga

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer

    Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer by Paul Cottu, Jamil Asselah, Marick Laé, J-Y Pierga, Véronique Dièras, L. Mignot, Brigitte Sigal‐Zafrani, Anne Vincent‐Salomon

    Published 2008
    Get full text Get full text
    Carta
    Save to List
    Saved in:
  8. 8
    New approaches for improving outcomes in breast cancer in Europe

    New approaches for improving outcomes in breast cancer in Europe by Angelo Di Leo, Giuseppe Curigliano, Véronique Dièras, Luca Malorni, Christos Sotiriou, Charles Swanton, Alastair M. Thompson, Andrew Tutt, Martine Piccart

    Published 2015
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  9. 9
    Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer

    Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer by Guy Jérusalem, Angelica Fasolo, Véronique Dièras, Fátima Cardoso, Jonas Bergh, Luc Vittori, Yufen Zhang, Cristian Massacesi, Tarek Sahmoud, Luca Gianni

    Published 2010
    Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy

    Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy by Ahmad Awada, Luc Dirix, Luís Manso, Binghe Xu, T Luu, Véronique Dièras, Dawn L. Hershman, V. Agrapart, Revathi Ananthakrishnan, Elżbieta Starosławska

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer

    Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer by Valentina Guarneri, David Miles, Nicholas J. Robert, Véronique Dièras, John A. Glaspy, Ian Smith, Christoph Thomssen, Laura Biganzoli, Tanya Taran, Pierfranco Conté

    Published 2010
    Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA

    Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exp... by Ian E. Krop, Nancy U. Lin, Kimberly Blackwell, Ellie Guardino, Jens Huober, Mengdi Lu, David Miles, Meghna Samant, Manfred Welslau, Véronique Dièras

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: An Integrated Safety Analysis

    Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: An Integrated Safety Analysis by Véronique Dièras, Nadia Harbeck, G. Thomas Budd, Joel K. Greenson, Alice E. Guardino, Meghna Samant, Nataliya Chernyukhin, Melanie C. Smitt, Ian E. Krop

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience

    Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience by L. Staudacher, P. Cottu, Véronique Dièras, Anne Vincent‐Salomon, M.N. Guilhaume, Lu Wang, Thierry Dorval, Philippe Beuzeboc, L. Mignot, Jean‐Yves Pierga

    Published 2010
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Survival of breast cancer patients with meningeal carcinomatosis

    Survival of breast cancer patients with meningeal carcinomatosis by H. Gauthier, M.N. Guilhaume, François‐Clément Bidard, Jean‐Yves Pierga, V. Girre, Paul Cottu, Valérie Laurence, Alain Livartowski, L. Mignot, Véronique Dièras

    Published 2010
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Characteristics and outcome of 1755 operable breast cancers in women over 70 years of age

    Characteristics and outcome of 1755 operable breast cancers in women over 70 years of age by Jean‐Yves Pierga, V. Girre, Valérie Laurence, Bernard Asselain, Véronique Dièras, M Jouve, Philippe Beuzeboc, Alain Fourquet, Claude Nos, Brigitte Sigal‐Zafrani, P Pouillart

    Published 2004
    Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: Report of the Clinical Screening Group of the EORTC

    A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: Report of the Clinical Screening Group of the EORTC by P. Fumoleau, B Chevallier, Pierre Kerbrat, Yvan Krakowski, J. L. Misset, C. Maugard-Louboutin, Véronique Dièras, N. Azli, Nathalie Bougon, A. Riva, Henri Roché

    Published 1996
    Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients

    High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic... by Jean‐Yves Pierga, David Hajage, Thomas Bachelot, Suzette Delaloge, Étienne Brain, Mario Campone, Véronique Dièras, Emilie Rolland, L. Mignot, Claire Mathiot, François‐Clément Bidard

    Published 2011
    Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells

    Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells by François‐Clément Bidard, Anne Vincent‐Salomon, Brigitte Sigal‐Zafrani, Véronique Dièras, Claire Mathiot, L. Mignot, Jean Paul Thiery, Xavier Sastre‐Garau, Jean‐Yves Pierga

    Published 2008
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC

    A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC by Véronique Dièras, B Chevallier, Pierre Kerbrat, I. Krakowski, Henri Roché, JL Misset, M-A. Lentz, N. Azli, M Murawsky, A. Riva, P Pouillart, P. Fumoleau

    Published 1996
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: